Silexion Adjourns Extraordinary Meeting to October 26; Reverse Split Range Narrowed to 1-for-15 to 1-for-25
SLXN is trading near its 52-week low of $0.142 (6.6% above the low).
Summary
Silexion adjourned its extraordinary general meeting to October 26 without voting on the 500 million share authorization increase and the reverse split, now capped at a 1-for-15 to 1-for-25 range. Both measures are needed to cure Nasdaq equity and bid price deficiencies after shareholders rejected a smaller package in September.
Key Events · Corporate Governance and Compliance · SLXN
-
Meeting Adjourned One Week
The extraordinary general meeting convened October 19, 2026 and was adjourned without conducting business; it reconvenes October 26, 2026. Record date remains September 29, 2026.
-
500M Share Authorization Increase
Proposal 1 would raise authorized capital from 15,900,000 to 515,900,000 ordinary shares at $0.135 par, adjusted downward if the reverse split passes. It is the stated route to restoring the $2.5 million shareholders' equity required by Nasdaq Rule 5550(b)(1).
-
Reverse Split Range Narrowed
Proposal 2 authorizes a reverse split of not less than 1-for-15 and not more than 1-for-25, with the Board setting the actual ratio before the meeting. The split targets the $1.00 minimum bid under Rule 5550(a)(2).
-
Prior Rejection and Delisting Pressure
Shareholders rejected a 175 million share increase and a 1-for-15 split on September 25, 2026, and the company received a Nasdaq Staff Determination letter on bid price deficiency the same day.
Analysis · SLXN · Life Sciences
A vote that was meant to settle Silexion's survival on Nasdaq has been pushed back a week, with no vote taken. Both proposals are existential: the 500 million share authorization increase is the company's route to rebuilding the $2.5 million shareholders' equity Nasdaq requires, and the reverse split is its route to the $1.00 minimum bid. Shareholders rejected a smaller version of both on September 25, and the company has since received a Nasdaq Staff Determination letter on bid price. The one new detail is that the reverse split ratio is now capped at 1-for-25 rather than left open-ended, which slightly limits how far the share count can be compressed. If either proposal fails again on October 26, the listing — which the company calls a critical asset — is at risk.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $0.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.14 to $36.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.